OpenURL Connection Search

Select item for more details and to access through your institution.

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. 194, doi. 10.1016/j.clml.2023.11.001
By:
- Martin, Thomas G.;
- Moreau, Philippe;
- Usmani, Saad Z.;
- Garfall, Alfred;
- Mateos, Maria-Victoria;
- San-Miguel, Jesus F.;
- Oriol, Albert;
- Nooka, Ajay K.;
- Rosinol, Laura;
- Chari, Ajai;
- Karlin, Lionel;
- Krishnan, Amrita;
- Bahlis, Nizar;
- Popat, Rakesh;
- Besemer, Britta;
- Martfnez-Lopez, Joaquin;
- Delforge, Michel;
- Trancucci, Danielle;
- Pei, Lixia;
- Kobos, Rachel
Publication type:
Article
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Published in:
Targeted Oncology, 2023, v. 18, n. 5, p. 667, doi. 10.1007/s11523-023-00989-z
By:
- Miao, Xin;
- Wu, Liviawati S.;
- Lin, Shun Xin Wang;
- Xu, Yan;
- Chen, Yang;
- Iwaki, Yuki;
- Kobos, Rachel;
- Stephenson, Tara;
- Kemmerer, Kristy;
- Uhlar, Clarissa M.;
- Banerjee, Arnob;
- Goldberg, Jenna D.;
- Trancucci, Danielle;
- Apte, Amit;
- Verona, Raluca;
- Pei, Lixia;
- Desai, Rachit;
- Hickey, Kathleen;
- Su, Yaming;
- Ouellet, Daniele
Publication type:
Article
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma.
Published in:
Cancer (0008543X), 2023, v. 129, n. 13, p. 2035, doi. 10.1002/cncr.34756
By:
- Martin, Thomas G.;
- Mateos, Maria Victoria;
- Nooka, Ajay;
- Banerjee, Arnob;
- Kobos, Rachel;
- Pei, Lixia;
- Qi, Ming;
- Verona, Raluca;
- Doyle, Margaret;
- Smit, Jennifer;
- Sun, Weili;
- Trancucci, Danielle;
- Uhlar, Clarissa;
- van de Donk, Niels W. C. J.;
- Rodriguez, Cesar
Publication type:
Article

Found: 3

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma.